Caris Discovery™, the therapeutic research arm of Caris Life Sciences®, announced a strategic partnership with Merck KGaA, Darmstadt, Germany to develop antibody-drug conjugates (ADC) for cancer patients. The partnership aims to discover novel targets to advance ADC therapeutics and eradicate tumors. Merck KGaA will provide upfront payment, research funding, milestones payments, and royalties to Caris, who will utilize their unique discovery platform to identify new therapeutic targets.
Under the agreement, Merck KGaA will have an exclusive global license to develop ADC therapeutics for selected targets discovered and validated by Caris. This collaboration will enhance Merck KGaA’s oncology portfolio and address unmet needs across multiple cancer types. Caris Discovery utilizes its molecular profiling business and AI capabilities to discover druggable targets that are inaccessible through traditional approaches, aiming to develop the next generation of oncology therapies in partnership with biopharma companies like Merck KGaA.
Caris Discovery’s approach involves leveraging its ADAPT Biotargeting™ platform, patient tissue repository, AI capabilities, and research laboratory to identify and validate new therapeutic targets. Merck KGaA will be responsible for the preclinical and clinical research, as well as the development and commercialization of drug candidates resulting from these programs. Together, Caris and Merck KGaA strive to bring new therapeutic options to cancer patients through precision therapeutics and innovative solutions revolutionizing healthcare.
Caris Life Sciences is a leading next-generation AI TechBio company and precision medicine pioneer, actively developing solutions to improve healthcare using molecular science and AI. Through comprehensive molecular profiling and advanced AI algorithms, Caris aims to provide precision medicine tools for early detection, diagnosis, therapy selection, and drug development. Headquartered in Irving, Texas, Caris has offices around the world and offers services internationally. Learn more about Caris Life Sciences by visiting their website.
